Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 4/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037716 | 0.88 | TLR8 (0.40) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL29315509 | 0.88 | TLR7 (0.39) | TGFBR1TLR8TLR7MAPT | |
| SCHEMBL23037710 | 0.83 | TLR7 (0.40) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL29320239 | 0.83 | TLR7 (0.41) | TLR8TLR7MEN1NPC1MAPT | |
| SCHEMBL30539925 | 0.83 | TLR7 (0.42) | TLR8TLR7 | |
| SCHEMBL29057282 | 0.82 | TLR7 (0.42) | TLR8TLR7MAPT | |
| SCHEMBL29320220 | 0.82 | TLR8 (0.37) | TLR8TLR7 | |
| SCHEMBL23037631 | 0.82 | TLR7 (0.44) | TLR8TLR7MAPT | |
| SCHEMBL27194816 | 0.82 | TLR8 (0.40) | TLR8TLR7ADORA3ADORA2AADORA1 | |
| SCHEMBL30539861 | 0.81 | TLR7 (0.43) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TGFBR1 2421/4885TLR8 210/4885TLR7 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.